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Abstract 
Background: Genomic instability is a hallmark of cancer cells, and this cellular phenomenon can emerge as a result 
of replicative stress. It is possible to take advantage of replicative stress, and enhance it in a targeted way to fight 
cancer cells. One of such strategies involves targeting the cell division cycle 7-related protein kinase (CDC7), a protein 
with key roles in regulation of initiation of DNA replication. CDC7 overexpression is present in different cancers, and 
small molecule inhibitors of the CDC7 have well-documented anti-tumor effects. Here, we aimed to test the potential 
of CDC7 inhibition as a new strategy for glioblastoma treatment.
Methods: PHA-767491 hydrochloride was used as the CDC7 inhibitor. Two glioblastoma cell lines (U87-MG and 
U251-MG) and a control cell line (3T3) were used to characterize the effects of CDC7 inhibition. The effect of CDC7 
inhibition on cell viability, cell proliferation, apoptosis, migration, and invasion were analyzed. In addition, real-time 
PCR arrays were used to identify the differentially expressed genes in response to CDC7 inhibition.
Results: Our results showed that CDC7 inhibition reduces glioblastoma cell viability, suppresses cell proliferation, and 
triggers apoptosis in glioblastoma cell lines. In addition, we determined that CDC7 inhibition also suppresses glio-
blastoma cell migration and invasion. To identify molecular targets of CDC7 inhibition, we used real-time PCR arrays, 
which showed dysregulation of several mRNAs and miRNAs.
Conclusions: Taken together, our findings suggest that CDC7 inhibition is a promising strategy for treatment of 
glioblastoma.
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Background
Glioblastoma is the most common malignant primary 
brain tumor. At the molecular level, glioblastoma is char-
acterized by unique genomic alterations, which are used 
to define four molecular subtypes [1]. The existence of 
distinct tumor subtypes creates a structural complexity, 
together with inherent resistance, limits the efficacy of 
available treatment strategies. These findings highlight 
the unmet need to develop novel therapeutic strategies 
for glioblastoma.
Conventional treatment strategies aim to inhibit cell cycle 
progression to attenuate tumor growth. An alternative 
approach involves enhancing replicative stress in a targeted 
manner, which can be exploited for therapeutic purposes 
[2]. One of the direct ways to accomplish this goal is to 
target cell division cycle 7-related protein kinase (CDC7). 
CDC7 is a serine/threonine kinase that phosphorylates 
minichromosome maintenance protein 2 (MCM2) of the 
eukaryotic pre-replication complex [3], and this step is 
required for initiation of DNA replication [4, 5]. Moreover, 
CDC7 overexpression is present in different cancer types 
[6–10]. Based on these findings, targeting CDC7 kinase was 
suggested as a new approach for cancer therapy [11].
Small molecule inhibitors of CDC7 were shown to have 
anti-tumor activity in different cancer types [12–14]. 
Open Access
Cancer Cell International
*Correspondence:  erdoganperkan@gmail.com 
†Zubeyde Erbayraktar and Begum Alural contributed equally to this work 
5 Pharmaplus Laboratories, Pharmaplus Ilac ve Saglik Urunleri Ltd. Sti, 
Izmir, Turkey
Full list of author information is available at the end of the article
Page 2 of 10Erbayraktar et al. Cancer Cell Int  (2016) 16:88 
PHA-767491 hydrochloride is one of the first-genera-
tion CDC7 inhibitors, and its anti-tumor activity is well 
characterized. Here, we report that CDC7 inhibition by 
PHA-767491 hydrochloride inhibits cell proliferation and 
induces apoptosis in glioblastoma cells. In addition, we 
found that CDC7 inhibition suppresses glioblastoma cell 
migration and invasion. By using real-time PCR arrays, 
we found that CDC7 inhibition alters the expression 
of several mRNAs and miRNAs in glioblastoma cells. 
In particular, CDC7 inhibition results in a significant 
decrease in cathepsin S mRNA and protein expression. 
Overall, our results indicate that CDC7 inhibition sup-
presses glioblastoma growth and invasiveness.
Methods
Cell culture
U87-MG, U251-MG, and 3T3 cells were obtained from 
American Tissue Culture Collection (ATCC). All cell 
lines were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), 2% l-glutamine, and 1% penicillin–strep-
tomycin. Cells were maintained at 37 °C and in 5% CO2 
atmosphere.
CDC7 inhibitor
PHA-767491 hydrochloride (Sigma-Aldrich, Germany) 
was used as the CDC7 inhibitor. Lyophilized PHA-
767491 hydrochloride was dissolved in nuclease-free 
water to achieve a final concentration of 5 mM, and ali-
quoted in 100 µl volume. Aliquots were stored at −20 °C, 
and a fresh aliquot was used for each experiment.
Cell viability assay
5×103 U87-MG and U251-MG cells were seeded in a 
96-well plate 24 h before treatment. Next day, cells were 
treated with inhibitor (10  µM final concentration), sol-
vent control (water), or left untreated. Seventy-two hours 
after treatment, 10 µl of PrestoBlue cell viability reagent 
(Invitrogen, Thermo Fisher Scientific, USA) was added 
onto the cells to assess cell viability. Relative cell viability 
was calculated by setting the viability of solvent control 
as 100%. Experiments were repeated at least three times.
Cell proliferation assay
For synchronization, U87-MG and U251-MG cells were 
maintained in culture medium supplemented with 1% 
FBS for 24  h. Then, 1  ×  104 U87-MG and U251-MG 
cells were seeded in a 96-well plate. Next day, cells were 
treated with inhibitor (2.5 or 10 µM final concentration), 
solvent control (water), or left untreated. Seventy-two 
hours after treatment, bromodeoxyuridine (BrdU) cell 
proliferation ELISA kit (Cell Signaling, #5492) was used 
according to the manufacturer’s instructions. Rate of 
proliferation in cells treated with solvent control was set 
as 100% to calculate relative cell proliferation rate.
Detection of cell death
U87-MG and U251-MG cells (5  ×  103 cells/well) were 
seeded in a 96-well plate. Next day, cells were treated 
with inhibitor [(2.5 or 10  µM final concentration), sol-
vent control (water), or left untreated. Twenty-four hours 
after treatment, cells were lysed, and cell death detection 
ELISAPlus kit (Roche, #11774425001) was used according 
to the manufacturer’s instructions. Relative level of DNA 
fragmentation (indicator of apoptosis) was calculated 
according to the following formula:
Immunoblotting
To analyze total MCM2 and p-MCM2 (S40 +  S41) pro-
tein levels, U87-MG and U251-MG cells were treated with 
PHA-767491 hydrochloride (10  µM final concentration) 
for 12  h. To analyze CTSS protein expression, U87-MG 
and U251-MG cells were treated with CDC7 inhibitor 
(2.5  µM final concentration), and cells were harvested at 
three different time points (24, 48, and 72 h). Afterwards, 
cells were lysed in a cocktail (RIPA buffer supplemented 
with protease and phosphatase inhibitors). Equal amount 
(50 µg) of protein samples were separated on 4–10% Tris–
Cl polyacrylamide gel, and proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes. The follow-
ing antibodies were used in Western blotting experiments: 
p-MCM2 (S40/S41) antibody (1:2000, abcam, ab70371); 
MCM2 antibody (1:1000, abcam, ab108935); cathepsin-
S (1:1000, abcam, ab134157) and beta-actin antibody 
(1:10,000, abcam, ab8227). After incubation with primary 
antibodies, membranes were subsequently incubated with 
HRP-labeled goat-anti-rabbit immunoglobulins (Santa 
Cruz). SuperSignal West Pico Chemiluminescent Sub-
strate (Thermo Scientific) was used for protein detection.
RNA isolation
miRNeasy kit (#217004; Qiagen GmbH, Hilden, Ger-
many) was used according to the manufacturer’s proto-
col to isolate total RNA from glioblastoma cells. RNA 
samples were eluted in nuclease-free water, and stored at 
−80 °C until further analysis.
Reverse‑transcription
RevertAid First Strand cDNA Synthesis Kit (#K1622; 
Thermo Scientific Fisher) was used to reverse-transcribe 
RNA samples for mRNA expression analysis. miScript 
RT II kit (Qiagen GmbH, Hilden, Germany) was used to 
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analysis. Equal amount (1 μg) of RNA samples were used 
for reverse transcription. cDNA samples were diluted 
with nuclease-free water, and stored at −20  °C until 
analysis.
Real‑time PCR
All real-time PCR experiments were performed on a 
LightCycler 480 instrument (Roche). In each experiment, 
three technical replicates per sample and a no-template 
control (NTC) were used. The following primer sequences 
were used: CTSS-F: GCCTGATTCTGTGGACTGG, 
CTSS-R: GATGTACTGGAAAGCCGTTGT; GAPDH-F: G 
CAAATTCCATGGCACCGT; GAPDH-R: TCGCCCCAC 
TTGATTTTGG. GAPDH was used as a housekeeping 
gene to normalize mRNA expression. Relative mRNA 
expression was calculated by using the formula 2−ddCt [15].
Migration assay
U87-MG and U251-MG cells were seeded at a density 
of 2.5   ×   105 cells/well in 6-well plates, and incubated 
in DMEM supplemented with 10% FBS for 24 h. A con-
fluent monolayer of each well was scratched with a 
200 μl pipette tip, and cells were washed twice with 1× 
PBS. Then, fresh growth medium containing 10% FBS, 
with or without CDC7 inhibitor (final concentration: 
2.5 or 10  µM) was added onto the cells. For each well, 
the wound area was marked, and images were acquired 
immediately after the scratch (0  h), and at 48  h on a 
phase-contrast inverted microscope (Olympus, CKX41; 
magnification: 10×). At each time point, the same 
wounded area was selected for image acquisition. The 
number of migrated cells was counted on ImageJ v.1.42 
software as described previously [16]. All experiments 
were performed in triplicate, and each experiment was 
repeated at least three times.
Invasion assay
Cell invasion experiments were performed using 24-well 
invasion chambers (pore size: 8  µm, 24 well; Greiner) 
coated with 250  µg/ml Matrigel (#356234; BD Biosci-
ence). U87-MG and U251-MG cells (2 × 104/well) were 
plated in medium without FBS, and 10% FBS in the bot-
tom chamber served as chemoattractant. Twenty-four 
hours after seeding, cells were stained with Diff-Quick 
Staining Set (#NC0674866; Siemens) and cells that did 
not cross the transfilter were removed with cotton swabs. 
Invaded cells were visualized by phase-contrast micros-
copy, and counted on Image J v.1.42 software.
Real‑time PCR arrays
Human Cancer Drug Targets PCR Array (PAHS-
507ZF-12; Qiagen GmbH, Hilden, Germany) and Brain 
Cancer miRNA PCR Array (MIHS-108Z; Qiagen GmbH, 
Hilden, Germany) were used to analyze the changes in 
cellular mRNA and miRNA expression profiles upon 
CDC7 inhibitor treatment. Twenty-four hours before 
treatment, 1 × 105 U87-MG cells were seeded in 6-well 
plates. Next day, cells were treated with inhibitor (final 
concentration: 2.5  µM) or solvent control (water). Total 
RNA isolation was performed as described previously. 
miScript RT II kit (Qiagen GmbH, Hilden, Germany) and 
RT2 First Strandt kit (Qiagen GmbH, Hilden, Germany) 
were used for reverse-transcription reactions. Input RNA 
amount was 400 ng for Human Cancer Drug Targets PCR 
array, and 500 ng for Brain Cancer miRNA PCR Array.
Three biological replicates were used for each real-time 
PCR experiment. All real-time PCR experiments were 
performed on a LightCycler 480 instrument (Roche). A 
cut-off value of 1.5-fold was used to identify the signifi-
cant hits.
Statistical analysis
All statistical analyses were performed on GraphPad 
Prism v.6.0 for Mac OS X (GraphPad Software, La Jolla, 
California, USA). Independent samples t test was used 
to analyze the differences between groups. P < 0.05 were 
considered as statistically significant.
Results
CDC7 inhibition decreases glioblastoma cell viability in a 
time‑ and dose‑dependent fashion
Inhibition of MCM2 phosphorylation at CDC7-depend-
ent site Ser40/41 is a pharmacodynamic parameter of 
CDC7 inhibition [12]. To confirm this finding, we treated 
U87-MG and U251-MG cells with PHA-767491 hydro-
chloride (10  µM final concentration) for 12  h, and ana-
lyzed total MCM2 and phospho-MCM2 (S40  +  S41) 
protein expression. Our results indicate that PHA-
767491 hydrochloride treatment leads to significant 
reduction in p-MCM2 (S40 + S41) expression both cell 
lines (Fig. 1a, b).
Next, we aimed to determine the half maximal inhibi-
tor concentration (IC50) of PHA-767491 hydrochloride. 
To do this, we treated U87-MG and U251-MG cells with 
different concentrations of PHA-767491 (0–10  µM) for 
72  h, and analyzed cell viability. For both cell lines, the 
IC50 concentration was approximately 2.5 µM (Fig. 1c).
After determining the IC50 value, we aimed to analyze 
how glioblastoma cell viability changes in response to 
CDC7 inhibition. We treated U87-MG and U251-MG 
cells with different concentrations of CDC7 inhibitor 
(2.5 and 10  µM final concentration), and determined 
that treatment with 2.5  µM PHA-767491 hydrochlo-
ride decreased cell viability by approximately 45% in 
both cell lines (Fig. 1d). Similarly, treatment with 10 µM 
PHA-767491 hydrochloride decreased cell viability 
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by approximately 75% in U87-MG cells, and 70% in 
U251-MG cells (Fig. 1e).
To explore the effects of CDC7 inhibition on non-tum-
origenic cells, we used non-transformed 3T3 cells as con-
trol cell line. Treatment with PHA-767491 hydrochloride 
resulted in a modest decrease in cell viability (Additional 
file  1: Fig.  S1a). On the other hand, we determined sig-
nificant decrease in cell proliferation (Additional file  1: 
Fig. S1b). Contrary to glioblastoma cells, CDC7 inhibition 
did not cause a significant increase in the level of DNA 
fragmentation in 3T3 cells (Additional file  1: Fig.  S1c). 
Overall, these findings indicate that PHA-767491 hydro-
chloride effectively decreases cell viability in glioblastoma 
cells in a time-dependent fashion, and CDC7 inhibition 
exerts limited effects on non-tumorigenic cells.
CDC7 inhibition inhibits glioblastoma cell proliferation, 
and induces apoptosis
PHA-767491 hydrochloride is able to induce apoptotic 
cell death [12], independent of p53 status of tumor cells. 
Our next question was to determine whether CDC7 
inhibition would also induce apoptosis in glioblastoma 
cells. We found that CDC7 inhibitor treatment for 24 h 
results in a significant increase in DNA fragmentation in 
both U87-MG cells (3.54-fold compared to control) and 
U251-MG cells (1.31-fold compared to control) (Fig. 2a). 
Under similar experimental conditions, we performed 
Annexin V staining, which also confirmed that CDC7 
inhibition induces apoptosis in both cell lines (Fig. 2b).
Another consequence of CDC7 inhibition is suppres-
sion of cell proliferation, which is demonstrated in mul-
tiple cell lines [12]. To determine if CDC7 inhibition also 
suppresses cell proliferation in glioblastoma cells, we 
used a chemiluminescent bromodeoxyuridine (BrdU) 
incorporation assay. Treatment with 2.5  µM of PHA-
767491 hydrochloride resulted in approximately 20% 
decrease in cell proliferation in both cell lines (Fig.  3). 
Similarly, treatment with 10 µM of PHA-767491 hydro-
chloride resulted in 96% decrease in cell proliferation 
in U87-MG cells, and 83% decrease in cell proliferation 
in U251-MG cells (Fig.  3). Taken together, these results 
demonstrate that CDC7 inhibition suppresses glioblas-
toma cell proliferation, and induces apoptosis.
CDC7 inhibition suppresses migration and invasion 
of glioblastoma cells
A common feature of glioblastoma cells is their aggres-
sive phenotype, which is characterized by their migration 
Fig. 1 CDC7 inhibition decreases glioblastoma cell viability in a time- and dose-dependent fashion. a Protein levels of total MCM2 and p-MCM2 
(S40 + S41) were analyzed with immunoblotting to confirm pharmacodynamic efficacy of CDC7 inhibition. Treatment with CDC7 inhibitor (10 μM) 
leads to a significant reduction in p-MCM2 (S40 + S41) expression in U87-MG and U251-MG cell lines. b ImageJ software was used to quantify the 
signal intensities in immunoblots. c U87-MG and U251-MG cells were treated with different concentrations of CDC7 inhibitor (0–10 μM) for 72 h to 
determine the IC50 value. d U87-MG and U251-MG cells were treated with CDC7 inhibitor (2.5 μM) for 24, 48, and 72 h, and PrestoBlue cell viability 
reagent (Thermo Fisher Scientific, #A13261) was used to assess cell viability. e Under similar experimental conditions, U87-MG and U251-MG cells 
were treated with CDC7 inhibitor (10 μM) for 24, 48, and 72 h, and cell viability was assessed as described previously. Data represent mean ±SEM. of 
three independent experiments. [*P < 0.05, **P < 0.01 and ***P < 0.001 for treated cells vs control]
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and invasion abilities. Our next goal was to identify 
whether CDC7 inhibition has any effect on glioblastoma 
cell migration and invasion. Using a wound-healing assay, 
we found that CDC7 inhibitor treatment caused a signifi-
cant decrease in the number of migrated cells in both cell 
lines (Fig. 4). At maximal dose (10 µM), we determined 
that the migration ability of both cell lines was dimin-
ished significantly (Fig.  4b, d). At IC50 dose, the degree 
of suppression was more prominent in U251-MG cells, 
compared to U87-MG cells.
In parallel, we also performed a transwell invasion 
assay to test the effect of CDC7 inhibition on glioblas-
toma cell invasion. Treatment with CDC7 inhibitor at 
maximal dose (10  µM) caused a significant decrease in 
number of invaded cells in both U87-MG cells (Fig. 5a, b) 
and U251-MG cells (Fig. 5c, d). However, at IC50 dose, the 
degree of inhibition was considerably less in U251-MG 
cells, compared to U87-MG cells. Taken together, these 
results indicate that CDC7 inhibition suppresses glio-
blastoma cell migration and invasion.
Molecular consequences of CDC7 inhibition at the 
transcriptomic level
To understand the molecular consequences of CDC7 
inhibition, we used commercial real-time PCR arrays 
to analyze the changes in expression levels of several 
mRNAs and miRNAs.
We found that 5 mRNAs were significantly upregu-
lated, and 4 mRNAs were significantly downregulated 
in U87-MG cells that were treated with CDC7 inhibitor. 
Pathway analysis and the list of differentially expressed 
genes is shown in Fig. 6a.
In parallel to mRNA expression analysis, we also aimed 
to identify how CDC7 inhibition alters the cellular miRNA 
profile. By using a commercial PCR array specific to known 
miRNAs related to different tumors of the brain and central 
nervous system, we determined that CDC7 inhibition leads 
to upregulation of hsa-miR-451a (2.34-fold) and hsa-miR-
320a (1.96-fold) in U87-MG cells. To validate the results 
of our profiling experiment, we used real-time PCR, and 
found that CDC7 inhibition results in 2.2-fold increase in 
miR-451a expression in U87-MG cells (Fig. 6e).
Fig. 2 CDC7 inhibition induces apoptosis in glioblastoma cells. U87-MG and U251-MG cells were treated with different concentrations of CDC7 
inhibitor (2.5 and 10 µM) for 24 h. Then, a Cell Death Detection ELISAPlus kit (Roche, #11544675001) and b Annexin-V staining were used to analyze 
apoptotic cell death. Data represent mean ± SEM of three independent experiments. [*P < 0.05, **P < 0.01 and ***P < 0.001 for treated cells vs 
control]
Fig. 3 CDC7 inhibition suppresses glioblastoma cell proliferation. 
U87-MG and U251-MG cells were treated with different concentra-
tions of CDC7 inhibitor (2.5 and 10 μM) for 72 h. Then, a chemilumi-
nescent BrdU incorporation assay (Cell Signaling, #5492) was used 
to analyze the rate of cell proliferation. Data represent mean ± SEM 
of two independent experiments. [*P < 0.05, **P < 0.01, ***P < 0.001 
and ****P < 0.0001 for treated cells vs control]
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We wanted to focus on CTSS, as it was the most sig-
nificantly downregulated target in the PCR array. To vali-
date our screening results, we analyzed CTSS mRNA and 
protein levels after CDC7 inhibitor treatment. Treatment 
with CDC7 inhibitor (2.5  µM) for 48  h resulted in 55% 
decrease in CTSS mRNA expression in U87-MG cells, 
and 48% decrease in U251-MG cells (Fig.  6c). Similarly, 
treatment with CDC7 inhibitor (2.5 µM) for 72 h caused 
a decrease in CTSS protein expression in U87-MG cells 
(Fig.  6b, d). Taken together, these results suggest that 
CDC7 inhibition may suppress glioblastoma growth 
through CTSS.
Discussion
Cancer cells override the checkpoints in cell cycle to sus-
tain continuous growth; however, this results in replica-
tive stress. Recently, it has been suggested that replicative 
stress can be enhanced in a targeted way to attenuate 
growth of cancer cells. In this regard, CDC7 has been 
suggested as a potential therapeutic target for p53-neg-
ative breast cancers [17], and other cancer types, as it is 
known to be overexpressed in multiple cancers [6, 18].
Commonly used inhibitors of DNA replication (includ-
ing topoisomerase inhibitors, intercalating agents, 
alkylating agents) lead to DNA damage, and activate the 
S-phase replication checkpoint (Chk1/Chk2-dependent 
checkpoint) [11]. Contrary to these agents, CDC7 inhibi-
tors are able to halt DNA replication, and induce apop-
tosis without activating the Chk1-dependent pathway 
[11]. This brings a therapeutic advantage to this class of 
agents.
PHA-767491 hydrochloride is a first-generation CDC7 
inhibitor with well-characterized anti-tumor activity. 
In the pioneering study, Montagnoli et  al. showed that 
PHA-767491 hydrochloride inhibits cell proliferation 
in a comprehensive panel of cancer cell lines at a mean 
Fig. 4 CDC7 inhibition suppresses glioblastoma cell migration. Cells were scratched with a pipette tip, and then incubated with CDC7 inhibi-
tor (10 μM) for 0–72 h. Migrating cells were visualized under a phase contrast microscope. a Representative images of migrated U87-MG and c 
U251-MG cells. b, d Image J-Cell counter plugin (https://imagej.nih.gov/ij/plugins/cell-counter.html) was used to quantify the number of migrated 
cells. Data represent mean ± SEM of three independent experiments. [*P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001 for treated cells vs 
control]
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IC50 value of 3.17  µM [12]. The authors also showed 
that PHA-767491 hydrochloride induces apoptosis in 
multiple cell lines [12]. In our study, we determined that 
PHA-767491 effectively reduces cell viability in both glio-
blastoma cell lines.
The IDH1 gene encodes isocitrate dehydrogenase 1, 
which is responsible for catalyzing the conversion of isoc-
itrate to alpha-ketoglutarate. The most common IDH1 
mutation is R132H, which produces a missense mutation 
that affects substrate binding ability of the enzyme. This 
mutation is commonly found in secondary glioblasto-
mas, and has clinical importance, as it is associated with 
improved survival in glioblastoma patients [19].
The IDH1 status of experimental cell models is a cru-
cial factor to consider when evaluating the therapeutic 
potential of CDC7 inhibition. The study by Ichimura 
et al. showed that none of the 15 glioblastoma cell lines 
(including U87-MG and U251-MG) has IDH1 mutations 
[20]. To address whether IDH1 status is associated with 
a differential response to CDC7 inhibition, further stud-
ies should be carried out on IDH1 wild-type and IDH1 
mutant cell lines.
The methylation of MGMT promoter is another factor 
that is associated with survival of glioblastoma patients. 
The MGMT gene encodes O6-methylguanine–DNA 
methyltransferase, which functions as a DNA-repair 
protein to remove alkyl groups from guanine residues. 
The methylation of MGMT promoter has a direct clini-
cal consequence, as it is associated with longer overall 
survival in patients with glioblastoma, who undergo a 
combination treatment consisting of radiotherapy and an 
alkylating agent (such as temozolomide) [21].
Both U87-MG and U251-MG cell lines have hyper-
methylated MGMT promoter [22, 23]. Considering that 
CDC7 inhibition with PHA-767491 does not elicit DNA 
damage response in recipient cells, it is possible that 
MGMT methylation status is not associated with a dif-
ferential response to CDC7 inhibition. The consequences 
of CDC7 inhibition should be compared between cell 
lines that have normal MGMT promoter and cell lines 
with hypermethylated MGMT promoter to reach a better 
conclusion.
To analyze the effects of CDC7 inhibition on non-
tumorigenic cells, we used 3T3 cell line as a model sys-
tem. Our results indicate that CDC7 inhibition leads to a 
slight decrease in cell viability, while causing a significant 
reduction in cell proliferation. In addition, CDC7 inhi-
bition does not induce apoptotic cell death in 3T3 cells, 
unlike glioblastoma cells. While CDC7 inhibition appears 
to cause selective cytotoxicity in glioblastoma cells, these 
results should be confirmed further in primary human 
astrocytes and other non-tumorigenic cells.
To understand the molecular consequences of CDC7 
inhibition, we used two commercial PCR arrays, which 
contain probes against (1) miRNAs known to be associ-
ated with brain and central nervous system tumors, and 
(2) mRNAs with roles in key intracellular signaling path-
ways. We determined that several important genes show 
differential expression in response to CDC7 inhibition. 
Considering that the majority of these genes are classified 
Fig. 5 CDC7 inhibition suppresses glioblastoma cell invasion. a Representative images of invaded U87-MG and c U251-MG cells after 24-h 
culture in Matrigel invasion chambers. b, d ImageJ-Cell counter plugin (https://imagej.nih.gov/ij/plugins/cell-counter.html) was used to quantify 
the number of invaded cells. The invasiveness of U87-MG and U251-MG cells was attenuated with the CDC7 inhibitor treatment. Data represent 
mean ± SEM of three independent experiments. [*P < 0.05, **P < 0.01 ***P < 0.001 and ****P < 0.0001 for treated cells vs control]
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as growth factors and receptors, it is possible that glio-
blastoma cells are trying to compensate the tumor sup-
pressive effect of CDC7 inhibition by activating key 
genes related to cell survival. This finding is particularly 
important, as it may allow predicting how cells are likely 
to develop chemoresistance over time. By identifying 
upregulated gene(s) and associated pathways, it may be 
possible to design combined therapies for glioblastoma.
hsa-miR-451a was one of the few miRNAs, which 
shows differential expression in response to CDC7 inhi-
bition. We determined that CDC7 inhibition leads to a 
2.3-fold increase in hsa-miR-451a expression in U87-MG 
cells. Previously, hsa-miR-451/AMPK complex was 
shown to work as a conditional switch to regulate glio-
blastoma cell migration and proliferation [24]. In case of 
glucose deprivation, hsa-miR-451 expression is reduced, 
which in turn leads to enhanced cell migration and sur-
vival [25]. In a recent study, Drusco et  al. found that 
miR-451, among several other miRNAs, is significantly 
upregulated in cerebrospinal fluid (CSF) sample of glio-
blastoma patients (>180-fold compared to normal) [26]. 
These findings are consistent with our results, which 
indicate that CDC7 inhibition results in upregulation of 
hsa-miR-451 expression and decreased cell migration.
Cathepsin S is a lysosomal cysteine protease, which 
is encoded by the CTSS gene. CTSS is overexpressed in 
Fig. 6 Dysregulated mRNAs and miRNAs in response to CDC7 inhibition. Commercial real-time PCR arrays were used to analyze differential mRNA 
and miRNA expression profiles in response to CDC7 inhibition. a List of cellular pathways analyzed by real-time PCR array. Differentially expressed 
mRNAs are indicated in italic. b, d Immunoblot analysis of CTSS in glioblastoma cell lines in response to CDC7 inhibition, and its quantification. c 
Real-time PCR analysis of CTSS mRNA expression levels in glioblastoma cell lines in response to CDC7 inhibition. e Analysis of miR-451 expression in 
U87-MG cell line in response to CDC7 inhibition [*P < 0.05, **P < 0.01 ***P < 0.001 and ****P < 0.0001 for treated cells vs control]
Page 9 of 10Erbayraktar et al. Cancer Cell Int  (2016) 16:88 
different cancer types (including astrocytomas [27]), 
and is reported to be an independent prognostic factor 
of survival for glioblastoma [28]. Previously, Zhang et al. 
reported that inhibition of CTSS expression induces 
autophagy and apoptosis in glioblastoma cell lines, 
through ROS-mediated PI3K/AKT/mTOR/p70S6K and 
JNK signaling pathways [29]. In another study, Kenig 
et  al. found a correlation between increased CTSS 
expression and invasiveness of glioblastoma cells [30]. 
Recently, Sevenich et al. reported that CTSS expression is 
significantly high in tumor cells in early stage metastases, 
and pharmacological inhibition of CTSS reduces experi-
mental brain metastasis [31].
Conclusion
In this study, we focused on multiple aspects of glioblas-
toma biology to understand the consequences of CDC7 
inhibition in vitro. We provided substantial evidence that 
CDC7 inhibition suppresses glioblastoma growth and 
invasiveness. In addition, our results provide preliminary 
evidence that CDC7 inhibition alters the glioblastoma 
transcriptome by upregulating and downregulating key 
genes involved in different cellular pathways. Notably, 
our results suggest that CDC7 inhibition may suppress 
glioblastoma growth through CTSS.
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